Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | IARS1 | P41252 | 1/20 | 0.32 |
| ▸ | TARS1 | P26639 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548932 | 1.00 | ADK (0.37) | ADKMARS1STING1ATMNSD3 | |
| SCHEMBL2548230 | 0.88 | MARS1 (0.39) | ADKMARS1STING1ATMNSD3 | |
| SCHEMBL2548239 | 0.88 | YAP1 (0.35) | ADKMARS1STING1NSD3 | |
| SCHEMBL2548233 | 0.85 | ALDH1A1 (0.39) | ADKMARS1STING1ATMNSD3 | |
| SCHEMBL2543337 | 0.84 | ADK (0.36) | ADKMARS1STING1ATMALDH1A1 | |
| SCHEMBL2541239 | 0.84 | ATM (0.42) | ADKMARS1STING1ATMALDH1A1 | |
| SCHEMBL12238556 | 0.84 | ATM (0.42) | ADKMARS1STING1ATMALDH1A1 | |
| SCHEMBL2541957 | 0.83 | FGFR1 (0.48) | ALDH1A1 | |
| SCHEMBL15633430 | 0.80 | ATM (0.40) | ADKATMALDH1A1 | |
| SCHEMBL15633431 | 0.80 | FGFR1 (0.39) | ADKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940313-B2 | Tyrosine-based prodrugs of antiviral agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2015-01-27 | — | — | US | disclosed |
| US-20110263535-A1 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | UNIVERSITY OF SOUTHERN CALIFORNIA | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263535-A1 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS | TYMP, MTAP, TK1 | ADK 80/4885MARS1 70/4885STING1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.